RitaS.AxelrodMD

Oncology • Philadelphia, PA

Professor Medical Oncology Thomas Jefferson University; Director, Jefferson Oncology Group

Join to view full profile

Dr. Axelrod is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Axelrod's full profile

Already have an account?

Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107
Phone+1 215-955-8874

Fax+1 215-955-2340

Education & Training

Main Line Health System/Lankenau Medical CenterFellowship, Hematology and Medical Oncology, 1975 - 1976
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1974 - 1975
Medical College of GeorgiaResidency, Internal Medicine, 1972 - 1973
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1970 - 1971
New York University School of MedicineClass of 1970

Certifications & Licensure

PA State Medical License 1974 - 2026
DE State Medical License 2017 - 2025
NJ State Medical License 1985 - 2025
NY State Medical License 1971 - 2014
GA State Medical License 1972 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
America's Top Doctors Castle Connolly, 2009-2014
Philadelphia Magazine Castle Connolly, 2005-2014
America's Top Doctors for Cancer Castle Connolly, 2008-2013
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Start of enrollment: 2007 Dec 01
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation Start of enrollment: 2004 Oct 01
Completed
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy Start of enrollment: 2013 Nov 11
Completed
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jul 22
Completed
Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer Start of enrollment: 2019 Jun 17
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma.
Eric V Mastrolonardo, Kathryn L Nunes, Pablo Llerena, Anastasia Nikitina, Anastasia Sobol
Clinical Cancer Research. 2025-02-03
3 citations
Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer.
Ramez Philips, Angela Alnemri, Dev Amin, Jena Patel, Michael C Topf
Cancer. 2024-03-15
1 citations
In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the...
Ayesha S Ali, Gregor Manukian, Jennifer M Johnson, Ioannis Vathiotis, Rita Axelrod
International Journal of Radiation Oncology, Biology, Physics. 2023-09-01

Press Mentions

Her Duty to HumanityOctober 29th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member